Medicine
Zarontin 250 mg/5 mL oral solution
Zarontin 250 mg/5 mL oral solution is a prescription medicine containing Ethosuximide for oral use, marketed by Parke-Davis, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Protect from freezing and light. Store at 20°–25°C (68° – 77°F), Preserve in…
Key facts
- Active ingredient (INN)
- Ethosuximide
- Brand
- Zarontin
- Strength
- 250 mg/5 mL
- Dosage form
- Oral solution
- Route
- Oral
- Packs
- 1 bottle
- Marketing authorisation holder
- Parke-Davis
- Manufacturer
- Parke-Davis
- Origin register
- US FDA, United States
- Storage
- Protect from freezing and light. Store at 20°–25°C (68° – 77°F), Preserve in tight containers.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N03AD01 Ethosuximide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 10 March 2020
- Identifiers
- RxCUI 251322, 755357DailyMed set ID 7bf3e616-45e8-4469-a75d-4d824ce951eaNDC 0071-2418Application ANDA080258
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 bottle, plastic in 1 carton / 474 mL in 1 bottle, plastic | 0071-2418-19 | Parke-Davis | 1 June 2022 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 2 November 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ethosuximide 250 mg/5 mL oral solution.
Other strengths and forms of Ethosuximide
Clinical summary
Ethosuximide is an anti-epileptic agent indicated for the control of absence (petit mal) epilepsy. It is available as capsules and oral solution. MedsAcross supplies Ethosuximide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about EthosuximideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zarontin prescribing information (Parke-Davis) · U.S. National Library of Medicine, DailyMed
Need Zarontin 250 mg/5 mL oral solution for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.